PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.28%
Revenue growth at 75-90% of META's 12.29%. Bill Ackman would push for innovation or market expansion to catch up.
11.12%
Gross profit growth similar to META's 12.33%. Walter Schloss would assume both firms track common industry trends.
19.30%
EBIT growth above 1.5x META's 10.27%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
19.30%
Operating income growth 1.25-1.5x META's 16.44%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
15.66%
Net income growth above 1.5x META's 10.17%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
15.44%
EPS growth 1.25-1.5x META's 10.47%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
15.28%
Diluted EPS growth 1.25-1.5x META's 11.04%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
0.25%
Slight or no buybacks while META is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.35%
Slight or no buyback while META is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
32.74%
OCF growth above 1.5x META's 6.39%. David Dodd would confirm a clear edge in underlying cash generation.
64.93%
Positive FCF growth while META is negative. John Neff would see a strong competitive edge in net cash generation.
2318.22%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
2318.22%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
360.83%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
501.21%
3Y OCF/share CAGR above 1.5x META's 125.05%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
2570.21%
Similar net income/share CAGR to META's 2770.56%. Walter Schloss would see parallel tailwinds or expansions for both firms.
2570.21%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
1706.56%
3Y net income/share CAGR above 1.5x META's 194.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
613.14%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.51%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
12.67%
Inventory growth of 12.67% while META is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
8.95%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
6.74%
1.25-1.5x META's 5.80%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
3.12%
R&D dropping or stable vs. META's 6.52%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
4.03%
SG&A declining or stable vs. META's 12.01%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.